1. Search Result
Search Result
Results for "

Mevalonate

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

10

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113071A
    Mevalonic acid lithium salt
    Maximum Cited Publications
    8 Publications Verification

    MVA lithium salt

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
    Mevalonic acid lithium salt
  • HY-W011474

    NF-κB Inflammation/Immunology
    Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .
    Geranylgeraniol
  • HY-W011209
    N6-Isopentenyladenosine
    1 Publications Verification

    Riboprine

    Autophagy Endogenous Metabolite Cancer
    N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .
    N6-Isopentenyladenosine
  • HY-N9474

    5-Diphosphomevalonic acid tetralithium; Mevalonic acid 5-diphosphate tetralithium

    Endogenous Metabolite Others
    Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .
    Mevalonic acid 5-pyrophosphate tetralithium
  • HY-113071

    MVA

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    Mevalonic acid
  • HY-113037

    Farnesyl diphosphate

    TRP Channel Endogenous Metabolite Neurological Disease
    Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
    Farnesyl pyrophosphate
  • HY-133957

    6-FluoroMevalonate; FMev

    Biochemical Assay Reagents Others
    6-Fluoromevalonate is a mevalonate-pyrophosphate decarboxylase inhibitor.
    Fluoromevalonate
  • HY-16274

    TAK-475

    Others Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-N7392

    Biochemical Assay Reagents Metabolic Disease
    Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
    Acetoacetyl-CoA
  • HY-107855
    DL-Mevalonolactone
    1 Publications Verification

    (±)-Mevalonolactone; Mevalolactone

    Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling [2][4].
    DL-Mevalonolactone
  • HY-107855S

    (±)-Mevalonolactone-d7; Mevalolactone-d7

    Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (∆Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling[1][2].
    DL-Mevalonolactone-d7
  • HY-113037C

    Farnesyl diphosphate ammonium

    TRP Channel Endogenous Metabolite Neurological Disease
    Farnesyl Pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
    Farnesyl Pyrophosphate ammonium
  • HY-151965

    Parasite Infection
    Antimalarial agent 18 is an potent antimalarial agent, based on electronic, highly lipophilic and siderophoric properties. Antimalarial agent 18 belongs to acyloxymethyl series, as a fosmidomycin surrogate, which is potent IspC inhibitor against the non-mevalonate isoprenoid biosynthesis pathway. Antimalarial agent 18 inhibits P. falciparum (IC50=50 nM) and A. baumanii (IC50=390 nM) .
    Antimalarial agent 18
  • HY-107855S1

    (±)-Mevalonolactone-d3; Mevalolactone-d3

    Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone[1]. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling[2][3].
    DL-Mevalonolactone-d3
  • HY-113071R

    MVA (Standard)

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    Mevalonic acid (Standard) is the analytical standard of Mevalonic acid. This product is intended for research and analytical applications. Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    Mevalonic acid (Standard)
  • HY-P1008

    Z-VD(OMe)VAD(OMe)-FMK

    Caspase Cancer
    Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis .
    Z-VDVAD-FMK

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: